Minzasolmin

Minzasolmin
Names
IUPAC name
N-[(2R)-1-(1H-indol-3-yl)hexan-2-yl]-2-(4-methylpiperazin-1-yl)-1,3-thiazole-5-carboxamide
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
KEGG
UNII
  • InChI=1S/C23H31N5OS/c1-3-4-7-18(14-17-15-24-20-9-6-5-8-19(17)20)26-22(29)21-16-25-23(30-21)28-12-10-27(2)11-13-28/h5-6,8-9,15-16,18,24H,3-4,7,10-14H2,1-2H3,(H,26,29)/t18-/m1/s1
    Key: GDFWCSZNQVAQGR-GOSISDBHSA-N
  • CCCC[C@H](CC1=CNC2=CC=CC=C21)NC(=O)C3=CN=C(S3)N4CCN(CC4)C
Properties
C23H31N5OS
Molar mass 425.60 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

Minzasolmin (development names DLX313 and UCB0599) is an experimental small-molecule drug in development for Parkinson's disease that is designed to prevent misfolding of α-synuclein.[1][2] On December 16, 2024 UCB reported the results of a phase II clinical trial on minzasolmin for Parkinson's involving 496 people, stating that the drug failed to demonstrate superiority over placebo in both primary and secondary endpoints.[3]

See also

References

  1. ↑ Schwarz, Thomas C.; Beier, Andreas; Ledolter, Karin; Gossenreiter, Thomas; Höfurthner, Theresa; Hartl, Markus; Baker, Terry S.; Taylor, Richard J.; Konrat, Robert (11 April 2023). "High-resolution structural information of membrane-bound α-synuclein provides insight into the MoA of the anti-Parkinson drug UCB0599". Proceedings of the National Academy of Sciences. 120 (15) e2201910120. Bibcode:2023PNAS..12001910S. doi:10.1073/pnas.2201910120. PMC 10104497. PMID 37027427. S2CID 258007748.
  2. ↑ Price, Diana L.; Khan, Asma; Angers, Rachel; Cardenas, Alvaro; Prato, Maria Key; Bani, Massimo; Bonhaus, Douglas W.; Citron, Martin; Biere, Anja-Leona (17 July 2023). "In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease". npj Parkinson's Disease. 9 (1): 114. doi:10.1038/s41531-023-00552-7. ISSN 2373-8057. PMC 10352257. PMID 37460603.
  3. ↑ Masson, Gabrielle (16 December 2024). "UCB-Novartis Parkinson's asset fails to improve symptoms". www.fiercebiotech.com. Retrieved 7 July 2026.
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.